Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

Clinical molecularly targeted chemoprevention has surged forward since the late 1990s, with several targeted agents that prevent cancers, intraepithelial neoplasias and/or microbial infections ...